Drug
AZD3759 clinical trials
Also written AZD3759.
- studies test it
- 4
- open now
- 0
- in phase 3
- 1
- first study started
- 2014
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
4 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 3
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 1
Alpha Biopharma (Jiangsu) Co., Ltd. (1) · LYZZ Alpha Holding Ltd (1) · AstraZeneca (1) · Guangdong Association of Clinical Trials (1)
Often tested with
Tested in the same studies.
Osimertinib (1) · Abivertinib (1) · Afatinib (1) · Crizotinib (1) · Ensartinib (1) · Tucidinostat (1) · Shr-1258 dimaleate (1) · Pirotinib (1)
Studies
Open first, then newest update. How each study uses AZD3759 is read from its arms, and is right about nine times in ten.
Testing it · 4
- First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) MetastasesCompletedPhase 2/3Alpha Biopharma (Jiangsu) Co., Ltd.NCT03653546Written as AZD3759
- Phase II Umbrella Study Directed by Next Generation SequencingStatus unknownPhase 2Guangdong Association of Clinical TrialsNCT03574402Written as AZD3759
- Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759CompletedPhase 1/2LYZZ Alpha Holding LtdNCT03360929Written as AZD3759
- Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung CancerCompletedPhase 1AstraZenecaNCT02228369Written as AZD3759
Codes
What other systems call AZD3759 · ClinicalTrials.gg INT000392
- MeSH (NLM) C000604577AZD3759One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000604577 | AZD3759 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.